恩格列净治疗初期eGFR下降的特征与意义:EMPA-REG OUTCOME试验分析
该研究为EMPA-REG OUTCOME试验的事后分析,纳入6668例2型糖尿病伴心血管疾病患者,按恩格列净治疗4周时eGFR变化分组。结果显示恩格列净组初始eGFR下降>10%的发生率高于安慰剂组(28.3% vs 13.4%,OR 2.7,95%CI 2.3-3.0),但该下降未显著影响恩格列净对心血管和肾脏结局的获益。
要点
- 恩格列净治疗初期eGFR下降>10%的发生率约28.3%,高于安慰剂的13.4%。
- 利尿剂使用和基线KDIGO风险类别较高可独立预测eGFR下降。
- 初始eGFR下降未显著改变恩格列净对心血管和肾脏结局的获益。
核心结论
- 恩格列净治疗初期eGFR下降>10%在晚期肾病或使用利尿剂的患者中更常见,但不影响其心血管和肾脏获益。
研究设计与样本
- EMPA-REG OUTCOME试验的事后分析,纳入6668例随机接受恩格列净10mg、25mg或安慰剂的2型糖尿病患者,按治疗4周时eGFR变化分组。
主要发现
- 恩格列净组初始eGFR下降>10%的发生率为28.3%,安慰剂组为13.4%,比值比2.7(95%CI 2.3-3.0)。
- 利尿剂使用和基线KDIGO风险类别较高是eGFR下降的独立预测因素。
- 初始eGFR下降未显著影响恩格列净对心血管死亡、心衰住院及肾脏疾病发生或恶化的治疗效果。
临床怎么用
- 对于使用利尿剂或基线KDIGO风险较高的2型糖尿病患者,恩格列净治疗初期可能出现eGFR下降>10%,但不应因此停药,因其心血管和肾脏获益不受影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment with sodium-glucose co-transporter-2 inhibitors induces an initial 3-5 ml/min/1.73 m2 decline in estimated glomerular filtration rate (eGFR). Although considered to be of hemodynamic origin and largely reversible, this 'eGFR dip' may cause concern in clinical practice, which highlights the need to better understand its incidence and clinical implications. In this post hoc analysis of the EMPA-REG OUTCOME trial, 6,668 participants randomized to empagliflozin 10 mg, 25 mg or placebo with eGFR available at baseline and week four were categorized by initial eGFR change into three groups; over 10% decline ('eGFR dipper'), over 0 and up to 10% decline ('eGFR intermediate'), no eGFR decline ('eGFR non-dipper'). Baseline characteristics of 'eGFR intermediate' and 'eGFR non-dipper' were generally comparable. An initial 'eGFR dip' was observed in 28.3% of empagliflozin versus 13.4% of placebo-treated participants; odds ratio 2.7 [95% Confidence Interval 2.3-3.0]. In multivariate logistic regression, diuretic use and higher KDIGO risk category at baseline were independently predictive of an 'eGFR dip' in empagliflozin versus placebo. Safety and beneficial treatment effects with empagliflozin on cardiovascular and kidney outcomes were consistent across subgroups based on these predictive factors. The initial 'eGFR dip' did not have a major impact on the treatment effect of empagliflozin on subsequent cardiovascular death, hospitalization for heart failure, and incident or worsening kidney disease. Thus, patients with type 2 diabetes with more advanced kidney disease and/or on diuretic therapy were more likely to experience an 'eGFR dip' of over 10% with empagliflozin, but reduction in cardiovascular and kidney outcomes was not relevantly modified by such 'eGFR dip.'
引用
- Kraus BJ, Weir MR, Bakris GL, et al. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2020. PMID: 33181154. doi:10.1016/j.kint.2020.10.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。